Mitoxantrone diacetate is a potenttopoisomeraseIIinhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with anIC₅₀of 8.5 μM. Mitoxantrone diacetate inducesapoptosisof B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity^[1][2][3][4]. Mitoxantrone diacetate also has anti-orthopoxvirusactivity withEC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively^[5].

Mitoxantrone diacetate inhibits PKC in a competitive manner with respect to histone H1, and its K_ivalue is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP^[1].
Mitoxantrone diacetate (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone diacetate induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone diacetate is due to induction of apoptosis^[2].
Mitoxantrone diacetate shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC₅₀values of 18 and 196 nM, respectively^[3].

Mitoxantrone diacetate (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia^[4].
Mitoxantrone diacetate (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma^[4].

564.58

C₂₆H₃₆N₄O₁₀

70711-41-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.